No. Starting TRT without blood work isn't considered safe under current clinical guidelines for diagnosing hypogonadism. The Endocrine Society and the American Urological Association both require 2 separate fasting morning testosterone measurements, combined with documented symptoms, before prescribing testosterone replacement therapy. About 30% of men with an initially low result return a normal value on repeat testing (Bhasin et al., 2018).
That 30% normalization rate alone justifies the 2-draw rule. Testosterone is a Schedule III controlled substance, and a lawful prescription requires a legitimate medical purpose supported by lab evidence and clinical evaluation. A licensed telehealth provider that follows current guidelines won't bypass blood work.
Why TRT Without Blood Work Is Not Safe
Pre-TRT blood work helps confirm the deficiency, identifies whether the cause is testicular or pituitary, and establishes safety baselines for markers that shift on testosterone, including hematocrit, PSA, and estradiol. The AUA classifies the 2-draw requirement as a Strong Recommendation with Grade A evidence (Mulhall et al., 2018).
Without labs, treatable causes like pituitary tumors go undetected. Potential contraindications, including elevated hematocrit, uncontrolled sleep apnea, and other conditions, go unscreened.
Population data sharpens the point. The European Male Ageing Study found that only 2.1% of men aged 40-79 met the full clinical definition of late-onset hypogonadism, defined as symptoms plus confirmed low testosterone (Wu et al., 2010). Biochemical low testosterone by lab value alone was far more common. Starting TRT based on symptoms without labs risks treating a condition that many symptomatic men may not have.
What Does a Pre-TRT Blood Panel Include?
The labs drawn before a first prescription serve different purposes. Some confirm the deficiency, others screen for contraindications, and a third group identifies the underlying cause.
|
Lab Category |
What It Includes |
Purpose |
|
Diagnostic (required) |
2 fasting morning total testosterone draws; free testosterone if borderline or altered SHBG |
Confirms deficiency per AUA and Endocrine Society |
|
Cause workup |
LH, FSH, prolactin |
Distinguishes testicular from pituitary disease |
|
Safety baseline |
CBC with hematocrit, PSA (age-appropriate), metabolic panel, blood pressure |
Identifies contraindications before first dose |
|
Metabolic context |
Fasting glucose or A1c, lipid panel |
Informs risk discussion; not a TRT indication |
Total and Free Testosterone
The AUA uses total testosterone below 300 ng/dL as a reasonable threshold to initiate a diagnostic discussion (Mulhall et al., 2018). Both fasting morning draws should fall between 8 and 10 AM, 1-3 weeks apart, using the same lab and assay. A diagnosis requires low levels plus symptoms. Level alone isn't enough.
When total testosterone sits near the lower limit, free testosterone by equilibrium dialysis may be needed. Obesity lowers SHBG, which can reduce total testosterone while free testosterone remains closer to normal.
SHBG (Sex Hormone-Binding Globulin)
SHBG binds testosterone and determines how much reaches tissue. High SHBG from aging or liver conditions can make total testosterone appear low even when free levels are adequate. Measuring SHBG helps prevent misclassification.
How LH Separates Primary From Secondary Hypogonadism
High LH with low testosterone points to primary testicular dysfunction (primary hypogonadism). Low or inappropriately normal LH with low testosterone suggests a pituitary or hypothalamic issue (secondary hypogonadism). That distinction changes the evaluation and treatment approach. When LH is low, prolactin testing helps evaluate for pituitary causes, including adenoma.
Does FSH Predict Fertility Risk on TRT?
FSH drives sperm production, and exogenous testosterone suppresses it. The Endocrine Society recommends against starting TRT when near-term fertility is planned (Bhasin et al., 2018). Recovery after stopping is variable and not guaranteed. A baseline FSH gives providers a reference point for the fertility conversation before treatment begins.
What Does a Complete Blood Count Reveal Before TRT?
Hematocrit is one of the most closely monitored safety markers on TRT. Testosterone stimulates red blood cell production, and unmonitored elevation is a recognized risk of unsupervised use. The Endocrine Society's intervention threshold sits at 54% (Bhasin et al., 2018). Without a baseline CBC, that threshold has no reference point.
PSA Screening Before Testosterone Therapy
A baseline PSA matters for on-treatment monitoring. The Endocrine Society recommends urological referral if PSA rises more than 1.4 ng/mL above baseline, exceeds 4.0 ng/mL, or a new exam abnormality appears in the first treatment year.
Estradiol and Aromatization on TRT
Testosterone converts to estradiol through aromatization. Measuring estradiol before and during treatment helps identify whether levels climb high enough to cause symptoms like gynecomastia or fluid retention. Management is individualized. There's no society mandate to add an aromatase inhibitor to every protocol.
Liver and Kidney Function
A metabolic panel screens for kidney function, and liver enzymes help establish baseline hepatic function before starting testosterone. Oral formulations in particular warrant hepatic screening. These panels also provide a baseline for on-treatment comparison.
Lipid Monitoring During Testosterone Therapy
TRT can shift lipid levels, most often HDL. A pre-treatment lipid panel provides the baseline. The FDA's February 2025 class-wide labeling update added a blood pressure warning to testosterone products while removing the earlier boxed cardiovascular warning after the TRAVERSE trial (FDA, 2025).
TRAVERSE (5,246 men, mean follow-up 33 months) showed a neutral primary MACE result (7.0% testosterone vs 7.3% placebo) but higher rates of atrial fibrillation (3.5% vs 2.4%), pulmonary embolism (0.9% vs 0.5%), and acute kidney injury (2.3% vs 1.5%) in the testosterone group (Lincoff et al., 2023).
How Often Should Blood Work Be Repeated on TRT?
The Endocrine Society recommends reassessing symptoms, measuring testosterone and hematocrit, and evaluating prostate cancer risk within 3-6 months after starting therapy or changing a dose (Bhasin et al., 2018). After that initial window, periodic monitoring continues at intervals the provider sets based on stability and individual risk.
Draw timing matters. Injectables create peak-and-trough patterns, so blood should be collected at trough before the next dose. Gels and patches produce steadier levels and are measured at a consistent morning time.
Reading TRT Blood Test Results
The Endocrine Society's treatment target is mid-normal for the assay used, adjusted for formulation-specific pharmacokinetics. A total testosterone of 800 ng/dL at peak on an injectable doesn't mean the same thing as 800 ng/dL on a daily gel.
Hematocrit, PSA, and estradiol matter alongside the testosterone level. A testosterone test result also depends on the assay, and the same sample can read differently between labs. Follow-up draws should use the same lab as the baseline to produce comparable numbers.
What Happens When Results Fall Outside the Target Range?
Low on-treatment testosterone may mean an insufficient dose, inconsistent adherence, or a formulation mismatch. High levels may signal a need for dose reduction, especially if hematocrit or estradiol are rising alongside.
Hematocrit above 54% generally prompts clinical reassessment, which may include dose reduction, a temporary hold, or therapeutic phlebotomy. PSA changes prompt urological referral per Endocrine Society thresholds. Blood pressure elevations, flagged in the February 2025 FDA update, warrant monitoring. None of these adjustments happen without the blood work that identifies them.
How Marek Diagnostics Approaches TRT Blood Work
Marek Diagnostics requires lab confirmation and clinical evaluation before prescribing testosterone. The process follows the 2-draw diagnostic standard, includes safety baselines, and builds in monitoring at defined intervals. Prescriptions are issued only when medically appropriate and where permitted by law.
Clients looking to get testosterone tested through a telehealth evaluation can expect blood work as part of the process. Starting TRT without blood work puts both the diagnosis and the client's safety at risk.
Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.
FAQs
Can you get a TRT prescription without any blood work?
No. Both the Endocrine Society and the AUA require 2 separate fasting morning testosterone measurements plus documented symptoms before prescribing testosterone. A provider who skips blood work is departing from the standard of care outlined by current guidelines for diagnosing hypogonadism.
Why does TRT require 2 separate blood tests instead of 1?
About 30% of men whose first testosterone result falls below 300 ng/dL return a normal value on repeat testing, according to the Endocrine Society's 2018 clinical practice guideline. A single draw can't distinguish transient fluctuation from true deficiency. The second draw, taken fasting between 8 and 10 AM on a separate day, confirms whether the low level is consistent.
What blood tests are checked before starting TRT?
A standard pre-TRT panel includes 2 fasting morning total testosterone draws, free testosterone (if borderline or SHBG is altered), LH, FSH, prolactin, CBC with hematocrit, PSA (age-appropriate), a metabolic panel, and a lipid panel. These labs confirm the diagnosis, identify the cause, and screen for safety contraindications.
Is it safe to start TRT without blood work if symptoms are obvious?
No. Symptoms alone don't confirm hypogonadism. The European Male Ageing Study found that only 2.1% of community-dwelling men aged 40-79 met the clinical definition of late-onset hypogonadism, which requires symptoms plus confirmed low testosterone. Many men with fatigue, low libido, or reduced energy have normal testosterone levels. Blood work, combined with clinical evaluation, helps distinguish those who may benefit from treatment.
How often should blood work be repeated once TRT starts?
The Endocrine Society recommends measuring testosterone, hematocrit, and prostate cancer risk markers within 3-6 months after starting therapy or adjusting a dose. After that, periodic monitoring continues at intervals the provider sets based on stability and individual risk factors.
What happens if blood work monitoring is skipped while on TRT?
Hematocrit, the percentage of red blood cells in the blood, rises on testosterone therapy. Without monitoring, it can exceed 54%, the threshold at which the Endocrine Society recommends intervention. Undetected hematocrit elevation is associated with increased thromboembolic risk. PSA changes, blood pressure shifts, and estradiol imbalances also go unidentified without follow-up labs.
Can a telehealth provider legally prescribe TRT after a video visit?
A DEA-registered prescriber, licensed in the patient's state, can prescribe Schedule III controlled substances like testosterone via telemedicine through December 31, 2026, under the fourth temporary extension of COVID-era flexibilities. The permanent rule isn't finalized, and state law may impose additional requirements. No provider can guarantee a prescription, and the 2-draw lab confirmation still applies regardless of how the evaluation is conducted.
Share:
Hormone Levels After Hysterectomy: What To Test And Why
Testosterone Cypionate Half Life And Duration In Your Body